PAVmed Inc. (PAVM)
NASDAQ: PAVM · IEX Real-Time Price · USD
2.240
-0.070 (-3.03%)
At close: May 2, 2024, 4:00 PM
2.090
-0.150 (-6.70%)
After-hours: May 2, 2024, 7:57 PM EDT
PAVmed Revenue
In the year 2023, PAVmed had annual revenue of $2.45M with 550.40% growth. Revenue in the quarter ending December 31, 2023 was $1.05M with 836.61% year-over-year growth.
Revenue (ttm)
$2.45M
Revenue Growth
+550.40%
P/S Ratio
8.62
Revenue / Employee
$22,916
Employees
107
Market Cap
21.13M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.45M | 2.08M | 550.40% |
Dec 31, 2022 | 377.00K | -123.00K | -24.60% |
Dec 31, 2021 | 500.00K | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Aesthetic Medical International Holdings Group | 96.27M |
Flora Growth | 76.07M |
Cumberland Pharmaceuticals | 39.55M |
DermTech | 15.30M |
Synlogic | 3.37M |
NeurAxis | 2.46M |
Sol-Gel Technologies | 1.55M |
OncoCyte | 1.50M |
PAVM News
- 21 hours ago - Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing - PRNewsWire
- 2 days ago - PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute - PRNewsWire
- 3 days ago - Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month - PRNewsWire
- 24 days ago - Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference - PRNewsWire
- 5 weeks ago - PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results - PRNewsWire
- 6 weeks ago - Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population - PRNewsWire
- 6 weeks ago - PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX - PRNewsWire
- 6 weeks ago - Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference - PRNewsWire